PDCD1 and metastatic melanoma: Among these PD-1/PD-L1 blockers, pembrolizumab (an anti-PD-1 antibody) is known to be one of the most potent immune checkpoint inhibitors (ICIs) and is approved for the treatment of metastatic melanoma in certain situations [7].